アフェレシスの市場規模：製品、手技、技術、用途、エンドユーザー、地域別、2024年～2031年

アフェレシス市場の規模と予測2024-2031

アフェレシス市場は、血液関連疾患の罹患率の上昇と治療的アフェレシス手技に対する需要の増加により、著しい成長を遂げています。また、アフェレシス装置やディスポーザブルの技術的進歩も、治療効果を高め、市場の拡大に寄与しています。このため、市場規模は2024年に39億9,000万米ドルを突破し、2031年には約63億米ドルに達する見込みです。

市場は世界的に拡大しており、北米が主要地域となっています。主な促進要因としては、ヘルスケア投資の増加や治療用アフェレシスに対する認知度の向上が挙げられます。アジア太平洋の新興市場も、患者数の増加とヘルスケア・インフラの改善に牽引され、牽引力を増しています。アフェレシスに対する需要の高まりにより、市場は2024年から2031年にかけてCAGR12.6%で成長する見込みです。

定義/概要

アフェレシスとは、血漿、血小板、白血球などの特定の血液成分を分離除去し、残りの血液を患者に戻すために用いられる医療処置です。

アフェレーシスは、自己免疫疾患、血液疾患、心血管疾患の治療に広く用いられています。また、血漿や血小板の採取を含む献血をサポートし、様々な臨床現場での患者ケアを向上させます。

アフェレシス市場は、技術の進歩、ヘルスケア・インフラの拡大、特に新興市場における血液成分療法への需要の増加により、将来的な成長が見込まれています。

血液関連疾患の増加はどのようにアフェレシス市場の成長を促進しますか？

自己免疫疾患、血液悪性腫瘍、心血管疾患などの血液関連疾患の頻度の増加が、アフェレシス産業を牽引しています。これらの疾患では特定の血液成分治療が頻繁に必要となるため、目的とする血液成分を分離・回収するアフェレシス手技の需要が高まっています。さらに、アフェレシス技術の革新と、これらの処置の利点に関するヘルスケア専門家の意識の高まりが、市場の拡大を後押ししています。アフェレシス研究開発への投資の増加は、治療の選択肢を広げ、患者の転帰を改善します。さらに、血液の問題に敏感な老年人口の増加が、効果的なアフェレシス治療への需要を高め、市場の成長を促進しています。全体として、血液関連疾患の有病率の増加は、アフェレシス市場の重要な促進要因です。

アフェレシス処置の高コストはどのようにアフェレシス市場の成長に課題となっているのか？

アフェレシス手術の高コストが市場の拡大を大きく制限しています。これらの治療には、専門的な機器、専門的な人材、病院の多大なリソースが頻繁に必要とされ、その結果、運営費が増加します。その結果、多くのヘルスケアプロバイダーはアフェレシス技術への投資をためらい、患者の治療へのアクセスが低下します。さらに、特に保険適用や財源が限られている地域では、高額な費用が個人やヘルスケアシステムに負担をかける可能性があります。この高額な障壁は、患者がアフェレーシスを選択することを妨げ、市場の需要を減少させる可能性があります。さらに、より安価な代替治療との競合がアフェレーシス市場の成長を阻害する可能性もあります。全体として、アフェレシス手術の高価格は、業界の長期的成長にとって大きな障壁となります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 アフェレシス市場：エンドユーザー別

• 病院とクリニック
• 血液銀行および輸血センター
• 外来手術センター

第5章 アフェレシス市場：技術別

• 遠心分離
• 膜ろ過

第6章 アフェレシス市場：用途別

• 治療用アフェレシス
• ドナーアフェレシス

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Fresenius SE & Co. KGaA
• Haemonetics Corporation
• Terumo Corporation
• B. Braun Melsungen AG
• Asahi Kasei Corporation
• Cerus Corporation
• Kawasumi Laboratories, Inc.
• HemaCare Corporation
• Kaneka Corporation
• Grifols, S.A.

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Apheresis Market Size And Forecast 2024-2031

The Apheresis Market is witnessing significant growth due to rising incidences of blood-related disorders and the increasing demand for therapeutic apheresis procedures. Technological advancements in apheresis devices and disposables are also contributing to the market's expansion, enhancing treatment efficacy. This is likely to enable the market size to surpass USD 3.99 Billion valued in 2024 to reach a valuation of around USD 6.3 Billion by 2031.

The market is expanding globally, with North America as the leading region. Key drivers include increasing healthcare investments and rising awareness of therapeutic apheresis. Emerging markets in Asia-Pacific are also gaining traction, driven by growing patient populations and improving healthcare infrastructure. The rising demand for apheresis is enabling the market to grow at aCAGR of 12.6% from 2024 to 2031.

Definition/Overview

Apheresis is a medical procedure used to separate and remove specific blood components, such as plasma, platelets, or white blood cells, while returning the remaining blood to the patient.

Apheresis is widely used in treating autoimmune disorders, hematological diseases and cardiovascular conditions. It also supports blood donations, including plasma and platelet collection, improving patient care in various clinical settings.

The apheresis market is poised for future growth, driven by advancements in technology, expanding healthcare infrastructure and increasing demand for blood component therapies, particularly in emerging markets.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Does the Rising Prevalence of Blood-Related Disorders Help in Driving the Growth Of The Apheresis Market?

The increasing frequency of blood-related ailments, such as autoimmune diseases, hematologic malignancies, and cardiovascular problems, is driving the apheresis industry. As these conditions frequently necessitate particular blood component therapy, the demand for apheresis procedures, which separate and collect targeted blood components, grows. Furthermore, innovations in apheresis technology and increasing awareness among healthcare professionals about the benefits of these procedures help to drive market expansion. Increasing investment in apheresis research and development expands treatment options and improves patient outcomes. Furthermore, the growing geriatric population, which is more sensitive to blood problems, increases the demand for effective apheresis treatments, driving market growth. Overall, the increasing prevalence of blood-related illnesses is a significant driver of the apheresis market.

How Is the High Cost of Apheresis Procedures Challenging the Growth Of The Apheresis Market?

The high cost of apheresis operations significantly limits the market's expansion. These treatments frequently necessitate specialized equipment, expert personnel, and substantial hospital resources, resulting in increasing operating expenses. As a result, many healthcare providers may hesitant to invest in apheresis technology, reducing patient access to these treatments. Furthermore, the high costs can put a strain on individuals and healthcare systems, particularly in areas with limited insurance coverage or financial resources. This expensive barrier may prevent patients from choosing for apheresis, reducing market demand. Furthermore, competition from less expensive alternative treatments may impede the apheresis market's growth. Overall, the high prices of apheresis operations represent a significant barrier to long-term industry growth.

Category-wise Acumens

How Will the Increasing Adoption of Automated Technologies Drive the Growth of The Apheresis Devices Segment?

The increasing adoption of automated technologies in apheresis devices is driving the growth of the segment by enhancing procedure accuracy, reducing manual errors and improving patient outcomes. These advanced devices offer greater efficiency in blood component separation, leading to their widespread use in both therapeutic and donation settings. As healthcare providers prioritize automation for better results and time savings, the demand for apheresis devices continues to grow, boosting the market segment's expansion.

How Will the Rising Use of Apheresis in Treating Autoimmune Disorders Drive the Growth of The Application Segment?

The rising use of apheresis in treating autoimmune disorders is driving growth in the Application segment by providing effective, targeted therapies for conditions like multiple sclerosis and Guillain-Barre syndrome. Apheresis helps remove harmful antibodies or immune complexes, offering significant clinical benefits. As the prevalence of autoimmune diseases increases, the demand for apheresis treatments expands, leading to the growth of this segment in both therapeutic and healthcare applications.

Country/Region-wise Acumens

Will The Advanced Healthcare Infrastructure Drive the Dominance of North America in The Apheresis Market?

North America's advanced healthcare infrastructure contributes significantly to the region's supremacy in the apheresis market. The well-established healthcare infrastructure make it easier to integrate innovative technologies, resulting in more efficient apheresis processes. Significant investments in cutting-edge medical technology improve the efficacy and accessibility of these therapies. Furthermore, growing awareness of the therapeutic benefits of apheresis, particularly for autoimmune diseases and hematologic disorders, is broadening the patient base. The region also benefits from a strong research climate, which promotes advances in apheresis technology. Additionally, regulatory backing and increasing healthcare expenditure help to drive market expansion. These factors combine to establish North America as a market leader in apheresis, fueling its sustained growth.

Will The Growing Healthcare Investments and Expanding Patient Population Drive the Rapid Growth of Asia-Pacific in The Apheresis Market?

The growing healthcare investments and expanding patient population are key drivers of Asia-Pacific's rapid growth in the Apheresis Market. As countries like China and India enhance their healthcare infrastructure, demand for advanced therapeutic procedures increases. Additionally, the rising prevalence of blood-related disorders and increasing awareness of apheresis treatments fuel market expansion. This combination of factors is positioning Asia-Pacific as the fastest-growing region in the global apheresis market.

Competitive Landscape

The apheresis market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Apheresis market include:

Asahi Kasei Corporation

Braun Melsungen AG

Cerus Corporation

Fresenius Kabi

Haemonetics Corporation

Charles River Laboratories International, Inc.

Kaneka Corporation

Kawasumi Laboratories Inc.

Nikkiso Co. Ltd

Terumo BCT

Latest Developments

In September 2024, Fresenius Kabi announced the divestment of its IV manufacturing site in Chile to Medifarma, streamlining its production network as part of its Vision 2026 strategy.

In June 2024, Asahi Kasei Corporation introduced a new membrane system for the production of sterile water used in injections, enhancing its product offerings in the healthcare sector.

In August 2023, Terumo BCT, Inc. launched a training program initiative aimed at supporting cell and gene therapy manufacturers, which is expected to improve cell collection processes and boost therapeutic commercialization.

In March 2024, Haemonetics Corporation received FDA approval for its new apheresis device designed to enhance the efficiency of blood component collection, marking a significant advancement in their product line.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Apheresis Market, By End User

• Hospitals and Clinics
• Blood banks and transfusion centers
• Ambulatory Surgical Centers

5. Apheresis Market, By Technology

• Centrifugation
• Membrane filtering

6. Apheresis Market, By Application

• Therapeutic apheresis
• Donor Apheresis

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Fresenius SE & Co. KGaA
• Haemonetics Corporation
• Terumo Corporation
• B. Braun Melsungen AG
• Asahi Kasei Corporation
• Cerus Corporation
• Kawasumi Laboratories, Inc.
• HemaCare Corporation
• Kaneka Corporation
• Grifols, S.A.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References